Morgan Stanley assumed coverage of Immunocore (IMCR) with an Equal Weight rating and $35 price target The firm remains positive on Kimmtrak sales, but believes sales expectations are largely reflected in the shares, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings: Pioneering HIV Cure with Promising Phase 1 STRIVE Trial Results
- Immunocore Reports 2024 Growth and Strategic Advances
- Immunocore’s Strategic Expansion and Robust Pipeline Drive Buy Rating
- Immunocore Holdings: Positive Earnings Call Highlights Growth
- Immunocore price target lowered to $85 from $88 at Oppenheimer